Celon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes

Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: We are very pleased about it. Our application was received a very good grade in the expert assessment and was placed high on the ranking. This project in the area of metabolic diseases is currently very important to us. First we are facing toxicological tests,Read more »

Announcement of the Management Board of Celon Pharma S.A.

Ladies and Gentlemen, In connection with the information provided yesterday by Selvita S.A. on withholding the clinical programme for SEL24, the Management Board of Celon Pharma S.A. informs that such situations occur naturally in the process of creating innovative medicinal products, as demonstrated by numerous examples of clinical projects carried out in American or EuropeanRead more »

An interview with Maciej Wieczorek in inwestorzy.tv

President of the Board of Celon Pharma S.A. was a guest of the programme Profit. He answered Agniszka Zaręba’s questions on the company’s results for the first half of 2017, on its presence in international markets and the strategy of global commercialisation of the company’s innovative portfolio. We invite you to view the video.